Status:
COMPLETED
Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome
Lead Sponsor:
French Cardiology Society
Conditions:
Acute Coronary Syndrome
Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of the VALIDE study is to validate that a 25% dose reduction of enoxaparine in patients with moderate renal failure (creatinine clearance between 30 and 50 ml/min) and hospitalized for a...
Detailed Description
Included patients will be those hospitalized for an acute coronary syndrome with indication of enoxaparin treatment. A same initial dose of 1 mg/kg will be administrated to all patients. According to ...
Eligibility Criteria
Inclusion
- Patients hospitalized for acute coronary syndrome
- Indication of enoxaparin treatment
- Informed consent
Exclusion
- Myocardial infarction with ST elevation
- Inclusion later than 12 hours after the first enoxaparin dose administration
- Creatinine clearance lower than 30 ml/min
- History of thrombopenia induced by heparin
- Platelet count lower than 100.000 / mm3
- Age \< 18
- Pregnancy
- History of hemorrhagic stroke
- Contra-indication to enoxaparin
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00412802
Start Date
December 1 2006
End Date
March 1 2009
Last Update
July 21 2011
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Sud Francilien Hospital center
Corbeil, Essonnes, France, 91100
2
CHU Jean MINJOZ
Besançon, France, 25030
3
Ambroise Paré Hospital
Boulogne, France, 92100
4
Henri Mondor Hospital
Créteil, France, 94010